Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus attenuated chemotherapy and Endu as first-line therapy for driver gene-negative advanced NSCLC (real-world, prospective cohort)
ChiCTR2400088216Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Public Health Clinical Center
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Shandong Provincial Public Health Clinical Center. Primary endpoint: Safety. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400088216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088216.